Description

Ipamorelin

• Ipamorelin is a synthetic pentapeptide and selective growth hormone secretagogue that stimulates endogenous growth hormone (GH) release by acting on the ghrelin (GHS‑R) receptor pathway.
• Investigational/clinical interest for supporting physiological GH secretion, body composition research, and recovery in controlled settings.

Key benefits (research findings)

• Stimulates pulsatile release of endogenous GH with minimal effect on cortisol and ACTH compared with some other secretagogues.
• May support improvements in lean body mass, recovery, and metabolic signaling in research models when combined with appropriate interventions.
• Often used in studies examining aging, muscle wasting, metabolic health, and recovery after injury.

Primary uses

• Research and clinical protocols investigating GH axis stimulation, sarcopenia, cachexia, metabolic regulation, and recovery.
• Used as a tool compound in endocrinology and translational physiology studies.

Suggested use

• Administered by subcutaneous injection per study or prescribing protocol; dosing, timing (often timed to exploit nocturnal GH pulses), and frequency vary by indication and trial design.
• Combination with other peptides (e.g., GHRP‑2/6, sermorelin, or chelated GH regimens) should follow clinician or protocol guidance.
• Use only under medical oversight with appropriate baseline and follow‑up endocrine monitoring.

Safety and storage

• Generally well tolerated in studied doses; possible adverse effects include injection‑site reactions, transient water retention, mild paresthesia, or headache. Monitor for GH‑related effects (e.g., glucose intolerance).
• Contraindications and precautions depend on medical history (e.g., active malignancy, uncontrolled diabetes)—consult a clinician before use.
• Handle and store lyophilized peptide per supplier instructions (commonly refrigerated or frozen for long‑term storage); reconstitute aseptically, aliquot, and minimize freeze–thaw cycles.

Quick facts

• Mechanism: ghrelin receptor (GHS‑R) agonist → stimulates endogenous GH release.
• Advantages: more selective GH stimulation with reduced ACTH/cortisol stimulation versus some secretagogues.
• Status: investigational for many indications; clinical use should occur only within approved protocols and under medical supervision.
• Procurement: available to research and clinical sites from legitimate suppliers with appropriate approvals.

Research Use Only Disclaimer

Products sold by SoCo Peptides are intended strictly for laboratory research purposes only.

These compounds are not intended for human consumption, veterinary use, household use, cosmetic use, or therapeutic application. They are not drugs, foods, or dietary supplements and have not been evaluated or approved by the FDA.

By purchasing from this website, the customer represents that they are a qualified researcher or laboratory professional and understand the risks associated with handling research materials.

All products must be handled by trained professionals in appropriate research facilities and in accordance with all applicable laws and regulations.

SoCo Peptides makes no guarantees or claims regarding safety, effectiveness, or medical benefit.